# A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

> **NCT04057937** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 90 (actual)

## Conditions studied

- Palmoplantaris Pustulosis

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04057937
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-16
- **Primary completion:** 2021-01-18
- **Final completion:** 2021-06-07
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04057937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04057937, "A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04057937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*